SCHEMBL29968508

SCHEMBL29968508

NC(=O)c1ccc(N2CCC(c3ccccc3)CC2)c(NC(=O)Nc2ccccc2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP14 Q460N5 5/20 0.50
MAPT P10636 5/20 0.49
KDM4E B2RXH2 2/20 0.49
LMNA P02545 4/20 0.48
TP53 P04637 3/20 0.48
GAA P10253 1/20 0.45
ALDH1A1 P00352 4/20 0.45
HPGD P15428 4/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 1/20 0.44
BTK Q06187 2/20 0.43
TNKS O95271 2/20 0.43
PARP1 P09874 2/20 0.43
HSD17B10 Q99714 1/20 0.43
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6797486 1.00 PARP14 (0.50) PARP14MAPTKDM4ELMNATP53
SCHEMBL6800041 0.87 NPC1 (0.55) MAPTKDM4ELMNAGAAALDH1A1
SCHEMBL29969862 0.87 NPC1 (0.55) MAPTKDM4ELMNAGAAALDH1A1
SCHEMBL6799649 0.85 CCR3 (0.55) PARP14MAPTKDM4ELMNATP53
SCHEMBL29968547 0.85 CCR3 (0.55) PARP14MAPTKDM4ELMNATP53
SCHEMBL6803523 0.84 MAPT (0.49) MAPTKDM4ELMNATP53GAA
SCHEMBL29968697 0.84 MAPT (0.49) MAPTKDM4ELMNATP53GAA
SCHEMBL6792633 0.80 LMNA (0.51) MAPTKDM4ELMNATP53GAA
SCHEMBL29968476 0.80 LMNA (0.51) MAPTKDM4ELMNATP53GAA
SCHEMBL6684996 0.80 KDM4E (0.53) MAPTKDM4ELMNATP53GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024189434-A1 USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) 2024-09-19 WO disclosed
CN-117999073-A Use of nadolol to treat chronic obstructive pulmonary disease by blocking the inhibitor protein-2 pathway 慢性呼吸道治疗有限公司 2024-05-07 CN disclosed
EP-4304717-A1 USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY Chronic Airway Therapeutics Limited (AU) 2024-01-17 EP disclosed
WO-2022192252-A1 USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) 2022-09-15 WO disclosed